Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Donna Gievers Zuniga

Podiatrist Olney, MD Doctor of Podiatric Medicine

NPI 1659349611 CMS profile 1263722

18111 Prince Philip Dr, 328, Olney, MD 20832

Open in the dashboard

General payments

$2,359

99 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Donna Gievers Zuniga of Olney, MD is reported in the CMS Open Payments database as having received $2,359 across 99 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $67 4
2024 General $61 2
2023 General $686 12
2022 General $234 10
2021 General $428 19
2020 General $519 27
2019 General $364 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Donna Gievers Zuniga
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Donna Gievers Zuniga were reported at $67. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Donna Gievers Zuniga Podiatrist median Middle half National median
2019 $364 $196 $72–$601 $163
2020 $519 $118 $38–$335 $114
2021 $428 $169 $57–$573 $132
2022 $234 $220 $74–$782 $149
2023 $686 $208 $71–$635 $160
2024 $61 $237 $87–$681 $164
2025 $67 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sunovion Pharmaceuticals Inc. $811 44 payments
  2. Djo, LLC $434 1 payment
  3. Relypsa, Inc. $277 11 payments
  4. Horizon Therapeutics plc $115 6 payments
  5. Sumitomo Pharma America, Inc. $94 4 payments
  6. Nevro Corp. $81 3 payments
  7. Kerecis Limited $66 3 payments
  8. Averitas Pharma Inc. $47 2 payments
  9. Sebela Pharmaceuticals Inc. $45 3 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $44 2 payments
  11. Other $344 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,924 98 payments
  2. Debt forgiveness $434 1 payment
Products named General payments · program years 2019–2025
  1. APTIOM $854 46 payments
  2. Veltassa $255 10 payments
  3. KRYSTEXXA $115 6 payments
  4. Omnia $81 3 payments
  5. Korsuva $80 3 payments
  6. Kerecis Omega3 SurgiClose $52 2 payments
  7. Kerecis Omega3 Marigen $52 2 payments
  8. Qutenza $47 2 payments
  9. NAFTIN $45 3 payments
  10. Kerendia $44 2 payments
  11. Other $721 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

286

Median for Podiatry: 160

Drug cost

$5,276

Median for Podiatry: $2,368

Branded share of claims

15.4%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ketoconazole Generic 139 $3,639
Mupirocin Generic 52 $481
Ciclopirox Ciclopirox Olamine Brand 32 $397
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 12 $207
Atorvastatin Calcium Generic 11 $205
Ammonium Lactate Generic 11 $171
Cephalexin Generic 18 $131
Famotidine Generic 11 $45

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$117,052

Medicare's payments for the services billed

Medicare patients

527

Average age 78

Services billed

2,377

335 women, 192 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 38%
Ischemic heart disease 30%
Chronic kidney disease 25%
Osteoporosis 22%
Depression 20%
Cancer 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $25
$25 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

99 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record